Roche is trading 4.81% up now at $58.20, outperforming the broader market as healthcare stocks rally.
- Healthcare ETF XLV is up 3.23% during the regular session, supported by earnings optimism, favorable regulatory conditions, increased deal activity, and rotation from technology into defensive growth stocks.
- Roche’s Genentech announced an IDEAYA pancreatic-cancer clinical collaboration on August 19, but available reporting does not establish it as the direct cause.